Cancer Pain - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Cancer pain is one of the most common symptoms in cancer patients. Pain can be caused by cancer, cancer treatment, or a combination of factors.

The global market for Cancer Pain was estimated to be worth US$ 6198 million in 2023 and is forecast to a readjusted size of US$ 8568 million by 2030 with a CAGR of 5.2% during the forecast period 2024-2030

Cancer Pain Market Size

M= millions and B=billions

The growth of the global cancer pain market is mainly due to the increasing prevalence of cancer; rising geriatric population; rising healthcare expenditure; and increasing investment in research and development activities by various healthcare companies. Due to aging effects and genetic mutations, older people are more prone to various types of cancer, such as lung cancer, bladder cancer, kidney cancer, melanoma, etc. According to the National Cancer Institute, the median age at diagnosis is 61 for breast cancer, 68 for colorectal cancer, 70 for lung cancer and 66 for prostate cancer. However, side effects associated with drugs used in cancer pain treatment, such as drug tolerance, drug dependence, urinary retention, sleep disturbance, cognitive impairment, etc., are expected to restrain the growth of the cancer pain market over the forecast period.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Pain, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cancer Pain by region & country, by Type, and by Application.

The Cancer Pain market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Pain.

Market Segmentation

• Report Metric

• Details

• Report Title

• Cancer Pain - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

• Forecasted Market Size in 2030

• US$ 8568 million

• CAGR(2024-2030)

• 5.2%

• Market Size Available for Years

• 2019-2030

• Global Cancer Pain Companies Covered

• BioDelivery Science, ProStrakan Group, Teva pharmaceuticals, Eli-Lilly, Grunenthal Group, GW Pharmaceuticals, Johnson＆Johnson, Meda Pharmaceuticals, Orexo, Sanofi, WEX Pharmaceuticals

• Global Cancer Pain Market, by Region

• North America (U.S., Canada, Mexico)

  Europe (Germany, France, UK, Italy, etc.)

  Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

  South America (Brazil, etc.)

  Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

• Global Cancer Pain Market, Segment by Type

• Opioids

  Non-Steroidal Anti-Inflammatory Drugs

  Others

• Global Cancer Pain Market, Segment by Application

• Radiotherapy

  Chemotherapy

  Hormone Therapy

  Others

• Forecast Units

• USD million in value

• Report Coverage

• Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cancer Pain manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Cancer Pain in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Cancer Pain in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

 1 Market Overview
    1.1 Cancer Pain Product Introduction
    1.2 Global Cancer Pain Market Size Forecast
    1.3 Cancer Pain Market Trends & Drivers
        1.3.1 Cancer Pain Industry Trends
        1.3.2 Cancer Pain Market Drivers & Opportunity
        1.3.3 Cancer Pain Market Challenges
        1.3.4 Cancer Pain Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Cancer Pain Players Revenue Ranking (2023)
    2.2 Global Cancer Pain Revenue by Company (2019-2024)
    2.3 Key Companies Cancer Pain Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Cancer Pain Product Offered
    2.5 Key Companies Time to Begin Mass Production of Cancer Pain
    2.6 Cancer Pain Market Competitive Analysis
        2.6.1 Cancer Pain Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Cancer Pain Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Pain as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Opioids
        3.1.2 Non-Steroidal Anti-Inflammatory Drugs
        3.1.3 Others
    3.2 Global Cancer Pain Sales Value by Type
        3.2.1 Global Cancer Pain Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Cancer Pain Sales Value, by Type (2019-2030)
        3.2.3 Global Cancer Pain Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Radiotherapy
        4.1.2 Chemotherapy
        4.1.3 Hormone Therapy
        4.1.4 Others
    4.2 Global Cancer Pain Sales Value by Application
        4.2.1 Global Cancer Pain Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Cancer Pain Sales Value, by Application (2019-2030)
        4.2.3 Global Cancer Pain Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Cancer Pain Sales Value by Region
        5.1.1 Global Cancer Pain Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Cancer Pain Sales Value by Region (2019-2024)
        5.1.3 Global Cancer Pain Sales Value by Region (2025-2030)
        5.1.4 Global Cancer Pain Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Cancer Pain Sales Value, 2019-2030
        5.2.2 North America Cancer Pain Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Cancer Pain Sales Value, 2019-2030
        5.3.2 Europe Cancer Pain Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Cancer Pain Sales Value, 2019-2030
        5.4.2 Asia Pacific Cancer Pain Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Cancer Pain Sales Value, 2019-2030
        5.5.2 South America Cancer Pain Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Cancer Pain Sales Value, 2019-2030
        5.6.2 Middle East & Africa Cancer Pain Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Cancer Pain Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Cancer Pain Sales Value
    6.3 United States
        6.3.1 United States Cancer Pain Sales Value, 2019-2030
        6.3.2 United States Cancer Pain Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Cancer Pain Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Cancer Pain Sales Value, 2019-2030
        6.4.2 Europe Cancer Pain Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Cancer Pain Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Cancer Pain Sales Value, 2019-2030
        6.5.2 China Cancer Pain Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Cancer Pain Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Cancer Pain Sales Value, 2019-2030
        6.6.2 Japan Cancer Pain Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Cancer Pain Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Cancer Pain Sales Value, 2019-2030
        6.7.2 South Korea Cancer Pain Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Cancer Pain Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Cancer Pain Sales Value, 2019-2030
        6.8.2 Southeast Asia Cancer Pain Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Cancer Pain Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Cancer Pain Sales Value, 2019-2030
        6.9.2 India Cancer Pain Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Cancer Pain Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 BioDelivery Science
        7.1.1 BioDelivery Science Profile
        7.1.2 BioDelivery Science Main Business
        7.1.3 BioDelivery Science Cancer Pain Products, Services and Solutions
        7.1.4 BioDelivery Science Cancer Pain Revenue (US$ Million) & (2019-2024)
        7.1.5 BioDelivery Science Recent Developments
    7.2 ProStrakan Group
        7.2.1 ProStrakan Group Profile
        7.2.2 ProStrakan Group Main Business
        7.2.3 ProStrakan Group Cancer Pain Products, Services and Solutions
        7.2.4 ProStrakan Group Cancer Pain Revenue (US$ Million) & (2019-2024)
        7.2.5 ProStrakan Group Recent Developments
    7.3 Teva pharmaceuticals
        7.3.1 Teva pharmaceuticals Profile
        7.3.2 Teva pharmaceuticals Main Business
        7.3.3 Teva pharmaceuticals Cancer Pain Products, Services and Solutions
        7.3.4 Teva pharmaceuticals Cancer Pain Revenue (US$ Million) & (2019-2024)
        7.3.5 Eli-Lilly Recent Developments
    7.4 Eli-Lilly
        7.4.1 Eli-Lilly Profile
        7.4.2 Eli-Lilly Main Business
        7.4.3 Eli-Lilly Cancer Pain Products, Services and Solutions
        7.4.4 Eli-Lilly Cancer Pain Revenue (US$ Million) & (2019-2024)
        7.4.5 Eli-Lilly Recent Developments
    7.5 Grunenthal Group
        7.5.1 Grunenthal Group Profile
        7.5.2 Grunenthal Group Main Business
        7.5.3 Grunenthal Group Cancer Pain Products, Services and Solutions
        7.5.4 Grunenthal Group Cancer Pain Revenue (US$ Million) & (2019-2024)
        7.5.5 Grunenthal Group Recent Developments
    7.6 GW Pharmaceuticals
        7.6.1 GW Pharmaceuticals Profile
        7.6.2 GW Pharmaceuticals Main Business
        7.6.3 GW Pharmaceuticals Cancer Pain Products, Services and Solutions
        7.6.4 GW Pharmaceuticals Cancer Pain Revenue (US$ Million) & (2019-2024)
        7.6.5 GW Pharmaceuticals Recent Developments
    7.7 Johnson＆Johnson
        7.7.1 Johnson＆Johnson Profile
        7.7.2 Johnson＆Johnson Main Business
        7.7.3 Johnson＆Johnson Cancer Pain Products, Services and Solutions
        7.7.4 Johnson＆Johnson Cancer Pain Revenue (US$ Million) & (2019-2024)
        7.7.5 Johnson＆Johnson Recent Developments
    7.8 Meda Pharmaceuticals
        7.8.1 Meda Pharmaceuticals Profile
        7.8.2 Meda Pharmaceuticals Main Business
        7.8.3 Meda Pharmaceuticals Cancer Pain Products, Services and Solutions
        7.8.4 Meda Pharmaceuticals Cancer Pain Revenue (US$ Million) & (2019-2024)
        7.8.5 Meda Pharmaceuticals Recent Developments
    7.9 Orexo
        7.9.1 Orexo Profile
        7.9.2 Orexo Main Business
        7.9.3 Orexo Cancer Pain Products, Services and Solutions
        7.9.4 Orexo Cancer Pain Revenue (US$ Million) & (2019-2024)
        7.9.5 Orexo Recent Developments
    7.10 Sanofi
        7.10.1 Sanofi Profile
        7.10.2 Sanofi Main Business
        7.10.3 Sanofi Cancer Pain Products, Services and Solutions
        7.10.4 Sanofi Cancer Pain Revenue (US$ Million) & (2019-2024)
        7.10.5 Sanofi Recent Developments
    7.11 WEX Pharmaceuticals
        7.11.1 WEX Pharmaceuticals Profile
        7.11.2 WEX Pharmaceuticals Main Business
        7.11.3 WEX Pharmaceuticals Cancer Pain Products, Services and Solutions
        7.11.4 WEX Pharmaceuticals Cancer Pain Revenue (US$ Million) & (2019-2024)
        7.11.5 WEX Pharmaceuticals Recent Developments

 8 Industry Chain Analysis
    8.1 Cancer Pain Industrial Chain
    8.2 Cancer Pain Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Cancer Pain Sales Model
        8.5.2 Sales Channel
        8.5.3 Cancer Pain Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. Cancer Pain Market Trends
    Table 2. Cancer Pain Market Drivers & Opportunity
    Table 3. Cancer Pain Market Challenges
    Table 4. Cancer Pain Market Restraints
    Table 5. Global Cancer Pain Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Cancer Pain Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Cancer Pain Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Cancer Pain Product Type
    Table 9. Key Companies Time to Begin Mass Production of Cancer Pain
    Table 10. Global Cancer Pain Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cancer Pain as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Cancer Pain Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Cancer Pain Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Cancer Pain Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Cancer Pain Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Cancer Pain Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Cancer Pain Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Cancer Pain Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Cancer Pain Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Cancer Pain Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Cancer Pain Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Cancer Pain Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Cancer Pain Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Cancer Pain Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Cancer Pain Sales Value by Region (2019-2024) & (%)
    Table 27. Global Cancer Pain Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Cancer Pain Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Cancer Pain Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Cancer Pain Sales Value, (2025-2030) & (US$ Million)
    Table 31. BioDelivery Science Basic Information List
    Table 32. BioDelivery Science Description and Business Overview
    Table 33. BioDelivery Science Cancer Pain Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Cancer Pain Business of BioDelivery Science (2019-2024)
    Table 35. BioDelivery Science Recent Developments
    Table 36. ProStrakan Group Basic Information List
    Table 37. ProStrakan Group Description and Business Overview
    Table 38. ProStrakan Group Cancer Pain Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Cancer Pain Business of ProStrakan Group (2019-2024)
    Table 40. ProStrakan Group Recent Developments
    Table 41. Teva pharmaceuticals Basic Information List
    Table 42. Teva pharmaceuticals Description and Business Overview
    Table 43. Teva pharmaceuticals Cancer Pain Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Cancer Pain Business of Teva pharmaceuticals (2019-2024)
    Table 45. Teva pharmaceuticals Recent Developments
    Table 46. Eli-Lilly Basic Information List
    Table 47. Eli-Lilly Description and Business Overview
    Table 48. Eli-Lilly Cancer Pain Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Cancer Pain Business of Eli-Lilly (2019-2024)
    Table 50. Eli-Lilly Recent Developments
    Table 51. Grunenthal Group Basic Information List
    Table 52. Grunenthal Group Description and Business Overview
    Table 53. Grunenthal Group Cancer Pain Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Cancer Pain Business of Grunenthal Group (2019-2024)
    Table 55. Grunenthal Group Recent Developments
    Table 56. GW Pharmaceuticals Basic Information List
    Table 57. GW Pharmaceuticals Description and Business Overview
    Table 58. GW Pharmaceuticals Cancer Pain Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Cancer Pain Business of GW Pharmaceuticals (2019-2024)
    Table 60. GW Pharmaceuticals Recent Developments
    Table 61. Johnson＆Johnson Basic Information List
    Table 62. Johnson＆Johnson Description and Business Overview
    Table 63. Johnson＆Johnson Cancer Pain Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Cancer Pain Business of Johnson＆Johnson (2019-2024)
    Table 65. Johnson＆Johnson Recent Developments
    Table 66. Meda Pharmaceuticals Basic Information List
    Table 67. Meda Pharmaceuticals Description and Business Overview
    Table 68. Meda Pharmaceuticals Cancer Pain Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Cancer Pain Business of Meda Pharmaceuticals (2019-2024)
    Table 70. Meda Pharmaceuticals Recent Developments
    Table 71. Orexo Basic Information List
    Table 72. Orexo Description and Business Overview
    Table 73. Orexo Cancer Pain Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Cancer Pain Business of Orexo (2019-2024)
    Table 75. Orexo Recent Developments
    Table 76. Sanofi Basic Information List
    Table 77. Sanofi Description and Business Overview
    Table 78. Sanofi Cancer Pain Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Cancer Pain Business of Sanofi (2019-2024)
    Table 80. Sanofi Recent Developments
    Table 81. WEX Pharmaceuticals Basic Information List
    Table 82. WEX Pharmaceuticals Description and Business Overview
    Table 83. WEX Pharmaceuticals Cancer Pain Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Cancer Pain Business of WEX Pharmaceuticals (2019-2024)
    Table 85. WEX Pharmaceuticals Recent Developments
    Table 86. Key Raw Materials Lists
    Table 87. Raw Materials Key Suppliers Lists
    Table 88. Cancer Pain Downstream Customers
    Table 89. Cancer Pain Distributors List
    Table 90. Research Programs/Design for This Report
    Table 91. Key Data Information from Secondary Sources
    Table 92. Key Data Information from Primary Sources
    Table 93. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Cancer Pain Product Picture
    Figure 2. Global Cancer Pain Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Cancer Pain Sales Value (2019-2030) & (US$ Million)
    Figure 4. Cancer Pain Report Years Considered
    Figure 5. Global Cancer Pain Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Cancer Pain Revenue in 2023
    Figure 7. Cancer Pain Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Opioids Picture
    Figure 9. Non-Steroidal Anti-Inflammatory Drugs Picture
    Figure 10. Others Picture
    Figure 11. Global Cancer Pain Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 12. Global Cancer Pain Sales Value Market Share by Type, 2023 & 2030
    Figure 13. Product Picture of Radiotherapy
    Figure 14. Product Picture of Chemotherapy
    Figure 15. Product Picture of Hormone Therapy
    Figure 16. Product Picture of Others
    Figure 17. Global Cancer Pain Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 18. Global Cancer Pain Sales Value Market Share by Application, 2023 & 2030
    Figure 19. North America Cancer Pain Sales Value (2019-2030) & (US$ Million)
    Figure 20. North America Cancer Pain Sales Value by Country (%), 2023 VS 2030
    Figure 21. Europe Cancer Pain Sales Value (2019-2030) & (US$ Million)
    Figure 22. Europe Cancer Pain Sales Value by Country (%), 2023 VS 2030
    Figure 23. Asia Pacific Cancer Pain Sales Value (2019-2030) & (US$ Million)
    Figure 24. Asia Pacific Cancer Pain Sales Value by Country (%), 2023 VS 2030
    Figure 25. South America Cancer Pain Sales Value (2019-2030) & (US$ Million)
    Figure 26. South America Cancer Pain Sales Value by Country (%), 2023 VS 2030
    Figure 27. Middle East & Africa Cancer Pain Sales Value (2019-2030) & (US$ Million)
    Figure 28. Middle East & Africa Cancer Pain Sales Value by Country (%), 2023 VS 2030
    Figure 29. Key Countries/Regions Cancer Pain Sales Value (%), (2019-2030)
    Figure 30. United States Cancer Pain Sales Value, (2019-2030) & (US$ Million)
    Figure 31. United States Cancer Pain Sales Value by Type (%), 2023 VS 2030
    Figure 32. United States Cancer Pain Sales Value by Application (%), 2023 VS 2030
    Figure 33. Europe Cancer Pain Sales Value, (2019-2030) & (US$ Million)
    Figure 34. Europe Cancer Pain Sales Value by Type (%), 2023 VS 2030
    Figure 35. Europe Cancer Pain Sales Value by Application (%), 2023 VS 2030
    Figure 36. China Cancer Pain Sales Value, (2019-2030) & (US$ Million)
    Figure 37. China Cancer Pain Sales Value by Type (%), 2023 VS 2030
    Figure 38. China Cancer Pain Sales Value by Application (%), 2023 VS 2030
    Figure 39. Japan Cancer Pain Sales Value, (2019-2030) & (US$ Million)
    Figure 40. Japan Cancer Pain Sales Value by Type (%), 2023 VS 2030
    Figure 41. Japan Cancer Pain Sales Value by Application (%), 2023 VS 2030
    Figure 42. South Korea Cancer Pain Sales Value, (2019-2030) & (US$ Million)
    Figure 43. South Korea Cancer Pain Sales Value by Type (%), 2023 VS 2030
    Figure 44. South Korea Cancer Pain Sales Value by Application (%), 2023 VS 2030
    Figure 45. Southeast Asia Cancer Pain Sales Value, (2019-2030) & (US$ Million)
    Figure 46. Southeast Asia Cancer Pain Sales Value by Type (%), 2023 VS 2030
    Figure 47. Southeast Asia Cancer Pain Sales Value by Application (%), 2023 VS 2030
    Figure 48. India Cancer Pain Sales Value, (2019-2030) & (US$ Million)
    Figure 49. India Cancer Pain Sales Value by Type (%), 2023 VS 2030
    Figure 50. India Cancer Pain Sales Value by Application (%), 2023 VS 2030
    Figure 51. Cancer Pain Industrial Chain
    Figure 52. Cancer Pain Manufacturing Cost Structure
    Figure 53. Channels of Distribution (Direct Sales, and Distribution)
    Figure 54. Bottom-up and Top-down Approaches for This Report
    Figure 55. Data Triangulation

Cancer pain is one of the most common symptoms in cancer patients. Pain can be caused by cancer, cancer treatment, or a combination of factors.

The global market for Cancer Pain was estimated to be worth US$ 6198 million in 2023 and is forecast to a readjusted size of US$ 8568 million by 2030 with a CAGR of 5.2% during the forecast period 2024-2030

The growth of the global cancer pain market is mainly due to the increasing prevalence of cancer; rising geriatric population; rising healthcare expenditure; and increasing investment in research and development activities by various healthcare companies. Due to aging effects and genetic mutations, older people are more prone to various types of cancer, such as lung cancer, bladder cancer, kidney cancer, melanoma, etc. According to the National Cancer Institute, the median age at diagnosis is 61 for breast cancer, 68 for colorectal cancer, 70 for lung cancer and 66 for prostate cancer. However, side effects associated with drugs used in cancer pain treatment, such as drug tolerance, drug dependence, urinary retention, sleep disturbance, cognitive impairment, etc., are expected to restrain the growth of the cancer pain market over the forecast period.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Pain, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Cancer Pain by region & country, by Type, and by Application.

The Cancer Pain market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Pain.

Market Segmentation

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Cancer Pain manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Cancer Pain in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Cancer Pain in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.